Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of MTX-531, a Dual EGFR/PI3K Inhibitor, as Monotherapy in Adults With Advanced Solid Tumors

NCT07874880 is registered in ClinicalTrials.gov with MEKanistic Therapeutics, Inc. as lead sponsor.

NCT NCT07874880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of MTX-531, a Dual EGFR/PI3K Inhibitor, as Monotherapy in Adults With Advanced Solid Tumors
Lead sponsor
MEKanistic Therapeutics, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 20, 2026
Completion date
September 29, 2029
Enrollment
71 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, head and neck squamous cell carcinoma, her2-negative metastatic breast cancer, hnscc, metastatic colorectal cancer (crc), pan-ras and braf wild-type advanced, solid tumors (phase 1)